Angela Lamarca, HPB and NET Medical Oncologist at Fundación Jiménez Díaz, Chair of ESMO Communication Commitee, shared on X:
“BGB-B2033 (GPC3-41BB) biespecific antibody in HCC at ESMO.
Promising data from phase I trial – ORR36%.
Heavily pre-treated population.
Development continues – phase III planned.”
You can also read: ACTICCA-1 at ESMO 2026: Adjuvant Gemcitabine Plus Cisplatin vs Capecitabine in Resected Biliary Tract Cancer.
